<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl0001">
 <label>Table 1</label>
 <caption>
  <p>Main attributes of licensed MS DMTs in relation to the COVID-19 pandemic</p>
 </caption>
 <alt-text id="alt0001">Table 1</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th valign="top">At risk category</th>
    <th valign="top">Class</th>
    <th valign="top">Trade name</th>
    <th valign="top">Mode of action</th>
    <th valign="top">Efficacy</th>
    <th valign="top">Class</th>
    <th valign="top">Safe to start treatment</th>
    <th valign="top">Advice regarding treatment</th>
    <th valign="top">In the event of COVID-19 infection?</th>
    <th valign="top">Immuosuppression?</th>
    <th valign="top">Attributes and caveats</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td valign="top">Very low</td>
    <td valign="top">Interferon-beta</td>
    <td valign="top">Betaferon, Avonex, Rebif, Plegridy</td>
    <td valign="top">Immunomodulatoy (not immunosuppressive), pleitropic immune effects</td>
    <td valign="top">Moderate</td>
    <td valign="top">Maintenance immunomodulatoy</td>
    <td valign="top">Yes</td>
    <td valign="top">Continue</td>
    <td valign="top">Continue</td>
    <td valign="top">No</td>
    <td valign="top">Has antiviral properties that may be beneficial in the case of COVID-19</td>
   </tr>
   <tr>
    <td valign="top">Very low</td>
    <td valign="top">Glatiramer acetate</td>
    <td valign="top">Copaxone</td>
    <td valign="top">Immunomodulatoy (not immunosuppressive), pleitropic immune effects</td>
    <td valign="top">Moderate</td>
    <td valign="top">Maintenance immunomodulatoy</td>
    <td valign="top">Yes</td>
    <td valign="top">Continue</td>
    <td valign="top">Continue</td>
    <td valign="top">No</td>
    <td valign="top"/>
   </tr>
   <tr>
    <td valign="top">Very low</td>
    <td valign="top">Teriflunomide</td>
    <td valign="top">Aubagio</td>
    <td valign="top">Dihydro-orotate dehydrogenase inhibitor (reduced de novo pyrimidine synthesis), anti-proliferative</td>
    <td valign="top">Moderate (1st-line) / Moderate to high (2nd-3rd-line)</td>
    <td valign="top">Maintenance immunomodulatoy</td>
    <td valign="top">Yes</td>
    <td valign="top">Continue</td>
    <td valign="top">Continue</td>
    <td valign="top">Possible (no well-defined immunosupressive signature)</td>
    <td valign="top">Has antiviral properties that may be beneficial in the case of COVID-19</td>
   </tr>
   <tr>
    <td valign="top">Low</td>
    <td valign="top">Dimethyl fumarate</td>
    <td valign="top">Tecfidera</td>
    <td valign="top">Pleotropic, NRF2 activation, downregulation of NFΚβ</td>
    <td valign="top">Moderate (2nd-3rd-line) / High (1st-line)</td>
    <td valign="top">Maintenance immunosuppressive</td>
    <td valign="top">Probably</td>
    <td valign="top">Continue / Switch if lymphopaenic</td>
    <td valign="top">Continue</td>
    <td valign="top">Yes, continous</td>
    <td valign="top">The risk can only be considered low in paients who don't develop a persistent lymphopaenia. Patients with a total lymphocyte count of less than 800/mm3 should be considered be at a higher risk of develping complications from COVID19 infection.</td>
   </tr>
   <tr>
    <td valign="top">Low</td>
    <td valign="top">Natalizumab</td>
    <td valign="top">Tysabri</td>
    <td valign="top">Anti-VLA4, selective adhesion molecule inhibitor</td>
    <td valign="top">Very high</td>
    <td valign="top">Maintenance immunosuppressive</td>
    <td valign="top">Yes</td>
    <td valign="top">Continue</td>
    <td valign="top">Continue or miss infusion depending on timing</td>
    <td valign="top">Yes, continous</td>
    <td valign="top">Low risk, but theoretical concerns of creating an environment in mucosal surfaces and the gut that may promote prolonged viral shedding. Also risk that as COVID-19/SARS-CoV-2 is neurotropic it may prevent viral clearance from the CNS.</td>
   </tr>
   <tr>
    <td valign="top">Intermediate</td>
    <td valign="top">S1P modulators</td>
    <td valign="top">Fingolimod (Gilenya), Siponimod (Mazent), Ozanimod, Ponesimod</td>
    <td valign="top">Selective S1P modulator, prevents egress of lymphocytes from lymph nodes</td>
    <td valign="top">High</td>
    <td valign="top">Maintenance immunosuppressive</td>
    <td valign="top">Probably</td>
    <td valign="top">Continue</td>
    <td valign="top">Continue or temporary suspension of dosing</td>
    <td valign="top">Yes, continous</td>
    <td valign="top">Theoretical risk that S1P modulators may result in prolonged viral shedding. Paradoxically S1P modulators may reduce the severity of COVID-19; fingolimod is currently being trialed.</td>
   </tr>
   <tr>
    <td valign="top">Intermediate</td>
    <td valign="top">Anti-CD20</td>
    <td valign="top">Ocrelizumab (Ocrevus), Ofatumumab. Rituximab, Ublituximab</td>
    <td valign="top">Anti-CD20, B-cell depleter</td>
    <td valign="top">Very high</td>
    <td valign="top">Maintenance immunosuppressive</td>
    <td valign="top">Probably</td>
    <td valign="top">Risk assessment - continue or suspend dosing</td>
    <td valign="top">Temporary suspension of dosing depending on timing</td>
    <td valign="top">Yes, continous</td>
    <td valign="top">Theoretical risk that ocrelizumab and other anti-CD20 therapies may result in prolonged viral shedding.</td>
   </tr>
   <tr>
    <td valign="top">Intermediate</td>
    <td valign="top">Cladribine</td>
    <td valign="top">Mavenclad</td>
    <td valign="top">Deoxyadenosine (purine) analogue, adenosine deaminase inhibitor, selective T and B cell depletion</td>
    <td valign="top">High / Very high (highly-active RMS)</td>
    <td valign="top">IRT (semi-selective)</td>
    <td valign="top">Probably</td>
    <td valign="top">Risk assessment - continue or suspend dosing</td>
    <td valign="top">Temporary suspension of dosing depending on timing</td>
    <td valign="top">Yes, intermittent</td>
    <td valign="top">Theoretical risk that in the immune depletion phase cladribine may result in prolonged viral shedding.</td>
   </tr>
   <tr>
    <td valign="top">High
     <xref rid="tb1fn1" ref-type="table-fn">*</xref>
    </td>
    <td valign="top">Mitoxantrone</td>
    <td valign="top">Novatrone</td>
    <td valign="top">Immune depleter (topoisomerase inhibitor)</td>
    <td valign="top">Very high</td>
    <td valign="top">IRT (non-selective)</td>
    <td valign="top">No</td>
    <td valign="top">Suspend dosing</td>
    <td valign="top">Suspend dosing</td>
    <td valign="top">Yes, intermittent</td>
    <td valign="top">Theoretical risk that in the immune depletion phase mitoxantrone may result in prolonged viral shedding.</td>
   </tr>
   <tr>
    <td valign="top">High
     <xref rid="tb1fn1" ref-type="table-fn">*</xref>
    </td>
    <td valign="top">Alemtuzumab</td>
    <td valign="top">Lemtrada</td>
    <td valign="top">Anti-CD52, non-selective immune depleter</td>
    <td valign="top">Very high</td>
    <td valign="top">IRT (non-selective)</td>
    <td valign="top">No</td>
    <td valign="top">Suspend dosing</td>
    <td valign="top">Suspend dosing</td>
    <td valign="top">Yes, intermittent</td>
    <td valign="top">Theoretical risk that in the immune depletion phase alemtuzumab may result in prolonged viral shedding.</td>
   </tr>
   <tr>
    <td valign="top">High
     <xref rid="tb1fn1" ref-type="table-fn">*</xref>
    </td>
    <td valign="top">HSCT</td>
    <td valign="top">-</td>
    <td valign="top">Immune depletion and haemopoietic stem cell reconstitution</td>
    <td valign="top">Very high</td>
    <td valign="top">IRT (non-selective)</td>
    <td valign="top">No</td>
    <td valign="top">Suspend dosing</td>
    <td valign="top">Suspend dosing</td>
    <td valign="top">Yes, intermittent</td>
    <td valign="top">Theoretical risk that in the immune depletion phase HSCT may result in prolonged viral shedding.</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn id="tb1fn1">
   <label>⁎</label>
   <p id="notep0001">risk refers to acquiring an infection during the immunodepletion phase. Post immune reconstitution the risk is low.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
